Abstract
Ruthenium-based complexes have a wide range of targets and mechanisms for anticancer activities. For the treatment of malignant malignancy, ruthenium-based drugs have special features. We establish the use of ruthenium-based complexes in the treatment of cancers throughout this review paper. The most common cause of cancer death is metastases, which alternate with primary tumors. Chemotherapy is generally ineffective against all solid human tumors and metastases. The ruthenium based complexes include metal-based complexes like NAMI-A and KP1019, as well as organometallic complexes like RM175, RAPTA-T, and RDC11. The ruthenium metal based complexes were discussed in this review study, together with the remaining clinical anticancer medicines, to explore tumor malignancy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
